Ironwood Pharma (IRWD) Was Downgraded to a Hold Rating at Craig-Hallum
Leerink Partners Maintains Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Maintains Target Price $1
Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Maintains Target Price $1
Jefferies Downgrades Ironwood Pharmaceuticals(IRWD.US) to Hold Rating, Cuts Target Price to $0.7
A Quick Look at Today's Ratings for Ironwood Pharmaceuticals(IRWD.US), With a Forecast Between $1 to $1
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7
Ironwood Pharmaceuticals Analyst Ratings
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $14
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
A Quick Look at Today's Ratings for Ironwood Pharmaceuticals(IRWD.US), With a Forecast Between $3 to $14
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $7
Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Cuts Target Price to $7
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Cuts Target Price to $7
Ironwood Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharma (IRWD) Gets a Buy From Craig-Hallum
Ironwood Pharmaceuticals: Strategic Focus on Apraglutide Drives Long-Term Growth Potential and Buy Rating
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Cuts Target Price to $14